Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kees Brinkman

Showing results (41-50 of 99) with videos related to

Pageof 10
Sort By:
AIDS (London, England)|February 19, 2005
Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort studyFerdinand Wnm Wit, Daniel H Blanckenberg, Kees Brinkman, et al.
AIDS (London, England)|April 9, 2009
Clinical experience with the combined use of lopinavir/ritonavir and rifampicinRafaëlla Fa L'homme, Hanneke M J Nijland, Luuk Gras, et al.
AIDS (London, England)|October 21, 2003
Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patientsMarchina E van der Ende, Jan M Prins, Kees Brinkman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2008
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort studyFerdinand W N M Wit, Anouk M Kesselring, Luuk Gras, et al.
AIDS (London, England)|October 3, 2003
Mortality and progression to AIDS after starting highly active antiretroviral therapyArd I van Sighem, Mark A van de Wiel, Azra C Ghani, et al.
AIDS (London, England)|April 2, 2014
Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infectionMerel M Heuft, Sanne M Houba, Guido E L van den Berk, et al.
AIDS (London, England)|May 9, 2009
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavirMarit G A van Vonderen, Paul Lips, Michiel A van Agtmael, et al.
The Journal of Clinical Endocrinology and Metabolism|February 26, 2013
Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE studyAoife G Cotter, Saskia M E Vrouenraets, Jennifer J Brady, et al.
Plos One|May 30, 2009
Zidovudine/lamivudine for HIV-1 infection contributes to limb fat lossMarit G A van Vonderen, Michiel A van Agtmael, Elly A M Hassink, et al.
Plos One|May 19, 2025
Longitudinal assessment of COVID-19 vaccine immunogenicity in people with HIV stratified by CD4+ T-cell count in the Netherlands: A two-year follow-up studyMarlou J Jongkees, Susanne Bogers, Rory D de Vries, et al.
Pageof 10

Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
AIDS (London, England)|February 19, 2005
Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort studyFerdinand Wnm Wit, Daniel H Blanckenberg, Kees Brinkman, et al.
AIDS (London, England)|April 9, 2009
Clinical experience with the combined use of lopinavir/ritonavir and rifampicinRafaëlla Fa L'homme, Hanneke M J Nijland, Luuk Gras, et al.
AIDS (London, England)|October 21, 2003
Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patientsMarchina E van der Ende, Jan M Prins, Kees Brinkman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2008
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort studyFerdinand W N M Wit, Anouk M Kesselring, Luuk Gras, et al.
AIDS (London, England)|October 3, 2003
Mortality and progression to AIDS after starting highly active antiretroviral therapyArd I van Sighem, Mark A van de Wiel, Azra C Ghani, et al.
AIDS (London, England)|April 2, 2014
Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infectionMerel M Heuft, Sanne M Houba, Guido E L van den Berk, et al.
AIDS (London, England)|May 9, 2009
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavirMarit G A van Vonderen, Paul Lips, Michiel A van Agtmael, et al.
The Journal of Clinical Endocrinology and Metabolism|February 26, 2013
Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE studyAoife G Cotter, Saskia M E Vrouenraets, Jennifer J Brady, et al.
Plos One|May 30, 2009
Zidovudine/lamivudine for HIV-1 infection contributes to limb fat lossMarit G A van Vonderen, Michiel A van Agtmael, Elly A M Hassink, et al.
Plos One|May 19, 2025
Longitudinal assessment of COVID-19 vaccine immunogenicity in people with HIV stratified by CD4+ T-cell count in the Netherlands: A two-year follow-up studyMarlou J Jongkees, Susanne Bogers, Rory D de Vries, et al.
Pageof 10